Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Group

www.ucb-group.com

Latest From UCB Group

Romosozumab Among Latest Drugs Up For CHMP Opinion

Four drugs are up for an opinion this week on whether they should be granted EU-wide approval, including Amgen/UCB's osteoporosis drug romosozumab.
Europe Approvals

UCB Buoyed By More Positive Bimekizumab Data

The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is confident bimekizumab’s mechanism of action, which neutralizes both IL-17A and IL-17F cytokines, offers an advantage over those two blockbusters.

Immune Disorders Clinical Trials

US FDA Approval Actions To Watch Out For In June

User fee goal date calendar for June includes AMAG’s female sexual dysfunction drug Vyleesi, new indications for Sanofi/Regeneron’s Dupixent in rhinosinusitis and Merck’s Zerbaxa in nosocomial pneumonia.

Drug Review Drug Approval Standards

Mereo Posts Early Upbeat Look At Brittle Bone Data For Setrusumab

The open-label Phase IIb data link setrusumab, licensed from Novartis, to improvements in bone density, offering encouragement for Mereo ahead of a critical upcoming readout for its lead program.

Clinical Trials Rare Diseases
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register